Abstract:Objective:To evaluate the clinical value of CT-guided 125I seeds implantation combining with 89SrCl 2 to relieve pain after failure of external irradiation in patients with bone metastases from prostate cancer. Methods:Clinical data of 48 patients (age 56-85 years) with bone metastases from prostate cancer admitted to General Hospital of the Northern Theater Command from January 2019 to June 2021 were retrospectively analyzed. Patients were treated with 125I seeds implantation combining with 89SrCl 2 (group A) and 89SrCl 2 alone (group B), respectively. Independent-sample t test and repeated measures analysis of variance were used to evaluate the differences of pain level (most severe pain, least pain, mean pain and current pain) scores and bone pain interference scores between 2 groups before and after treatment (before treatment, 3 d, 4 weeks, 8 weeks and 12 weeks after treatment). Prostate specific antigen (PSA), free PSA (fPSA) and alkaline phosphatase (ALP) 12 weeks after treatment of 2 groups were also compared by using independent-sample t test. Results:In group A, a total of 722 seeds were implanted in 39 bone metastases in 23 patients, and the implantation successful rate was 97.44%(38/39). There were 25 patients in group B. In group A, the most severe pain, mean pain and current pain scores decreased with time ( F values: 3.71-22.47, all P<0.05). Except for the scores at 3 d posttreatment, most severe pain, mean pain, and current pain scores at different times showed significant differences with those before treatment (all P<0.05). There were also differences in the most severe pain, mean pain, and current pain scores in group B before and after treatment ( F values: 2.45-2.52, P values: 0.044-0.049), with scores decreasing first (till 8 weeks after treatment) and increasing later. The most severe pain, mean pain, and current pain scores 8 week after treatment were lower than those before treatment (all P<0.05), but all the four scores at 12 weeks were not significantly different from those before treatment ( P values: 0.057-0.693). At 12 weeks after treatment, the differences in the most severe pain, mean pain and current pain scores between 2 groups were statistically significant ( t values: 2.04-3.41, P values: 0.001-0.047). Bone pain interference scores 12 weeks after treatment in group A were higher than those in group B ( t values: 2.04-3.16, P values: 0.022-0.047), and PSA, fPSA and ALP 12 weeks after treatment in group A were significantly lower than those in group B ( t values: 4.38-6.82, P values: 0.012-0.042). Conclusion:CT-guided 125I seeds implantation combined with 89SrCl 2 is feasible and effective for the treatment of bone pain after failed external irradiation in patients with prostate cancer bone metastases, especially for the combination of fulminant pain.

I Seed Implant Brachytherapy For Painful Bone Metastases After Failure Of External Beam Radiation Therapy

I-125 Brachytherapy In The Palliation Of Painful Bone Metastases From Lung Cancer After Failure Or Rejection Of Conventional Treatments

125I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments.

CT-Guided 125I Seed Interstitial Brachytherapy As a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy.

Clinical Study CT-Guided 125 I Seed Interstitial Brachytherapy as a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy

Ultrasound-Guided I Seed Implantation in Treatment of Abdominal Wall Metastases.

Brachytherapy by Percutaneous Paracentesis Implantation of Iodine-125 Seeds for Lung Cancer

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study.

CT-guided radioactive 125I seeds implantation in treatment of spinal metastatic tumors

Computed Tomography (CT)-guided Interstitial Permanent Implantation of 125I Seeds for Refractory Chest Wall Metastasis or Recurrence

CT-guided Permanent 125I Seed Interstitial Brachytherapy for Recurrent Retroperitoneal Lymph Node Metastases after External Beam Radiotherapy

Clinical efficacy of CT-guided 125 I seed brachytherapy in the treatment of metastatic hepatic carcinoma

Computed Tomography Fluoroscopy-Guided Percutaneous 125I Seed Implantation for Safe, Effective and Real-Time Monitoring Radiotherapy of Inoperable Stage T1-3N0M0 Non-Small-cell Lung Cancer.

Computed Tomography (Ct)-Guided Interstitial Permanent Implantation of (125)I Seeds for Refractory Chest Wall Metastasis or Recurrence.

The Safety and Efficacy of Interstitial 125I Seed Implantation Brachytherapy for Metastatic Epidural Spinal Cord Compression

Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer

Clinic Efficacy of CT-guided ~(125)I Seeds Implantation Therapy in Patients with Advanced Vertebrae Metastatic Tumor

Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases

CT-guided 125 I Seed Brachytherapy for Superficial Lymph Node Metastases:A Report of 23 Cases

Clinical value of CT-guided 125I seeds combining with 89SrCl 2 in relieving pain of patients with bone metastases from prostate cancer after failure of external irradiation

Survival of Patients with Advanced Pancreatic Cancer after Iodine125 Seeds Implantation Brachytherapy